SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-209678
Filing Date
2023-08-11
Accepted
2023-08-11 06:09:51
Documents
14
Period of Report
2023-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d519254d8k.htm   iXBRL 8-K 25379
2 EX-99.1 d519254dex991.htm EX-99.1 54800
6 GRAPHIC g519254g56g39.jpg GRAPHIC 3195
  Complete submission text file 0001193125-23-209678.txt   214874

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20230811.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20230811_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20230811_pre.xml EX-101.PRE 11262
8 EXTRACTED XBRL INSTANCE DOCUMENT d519254d8k_htm.xml XML 3367
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 231161408
SIC: 2834 Pharmaceutical Preparations